Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 11 - 14 crawled time : 01:00 save search
Innovent Presents Clinical Data of Phase Ia Study for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Solid Tumors at the 2022 Chinese Society of Clinical Oncology (CSCO) Annual Meeting
Published: 2022-11-14 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: -1.6%
H: 0.0%
C: 0.0%
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: 1.92%
H: 0.48%
C: -0.84%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 0.84%
H: 0.0%
C: 0.0%
INCY | $51.74 0.17% 0.14% 1.6M
|
Health Technology
|
| O: 0.22%
H: 0.86%
C: -0.79%
ibi351 meeting chinese tumors study
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.